Oak Lawn, Illinois Clinical Trials

A listing of Oak Lawn, Illinois clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 743 clinical trials
featured
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

www.MyelofibrosisResearch.com This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.

University of Chicago /ID# 164115
 (8.8 away) Contact site
  • 251 views
  • 29 Apr, 2021
  • +134 other locations
featured
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.  

FGFR2
cancer
primary cancer
metastatic cancer
University of Chicago Medical Center
 (8.8 away) Contact site
  • 154 views
  • 14 Dec, 2020
  • +154 other locations
featured
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

This is an open-label, monotherapy study of INCB054828 in subjects with myeloid/lymphoid neoplasms with FGFR1 rearrangement.  Subjects will receive a once daily (QD) dose of INCB054828 at 13.5 mg on a 2-week-on–therapy and 1-week-off–therapy schedule.  With Protocol Amendment 3, the administration schedule will be adjusted, and newly enrolled subjects will …

FGFR1
lymphoid malignancy
myeloid neoplasm
The University of Chicago Medical Center
 (8.9 away) Contact site
  • 79 views
  • 14 Dec, 2020
  • +34 other locations
featured
ECOSPOR III: A Phase 3 Multicenter, RandomizeEd, Double Blind, Placebo COntrolled, Parallel Group Study to Evaluate the Safety, Tolerability, & Efficacy of SER-109 vs. Placebo to Reduce Recurrence of ClOstRidium Difficile Infection (CDI) in Adults

ECOSPOR III is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the safety, tolerability, and efficacy of SER-109 versus placebo in adult subjects 18 years of age or older with recurrent CDI, defined as: a history of ≥ 3 CDI episodes within 9 months, inclusive of the current …

vancomycin
clostridium difficile
antibiotic therapy
antibiotics
fidaxomicin
The University of Chicago Medical Center
 (8.8 away) Contact site
  • 1092 views
  • 21 Dec, 2020
  • +71 other locations
featured
ECOSPOR IV: An Open-Label Extension of Study SERES-012 and Open-Label Program for Evaluating SER-109 in Adult Subjects with Recurrent Clostridioides difficile Infection (RCDI)

ECOSPOR IV is a Phase 3, multicenter, Open Label study to evaluate the safety and tolerability of SER-109 in adult subjects with recurrent CDI.

clostridium difficile
The University of Chicago Medical Center
 (8.8 away) Contact site
  • 37 views
  • 21 Dec, 2020
  • +76 other locations
featured
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors Carcinoma

The purpose of this study is to determine the safety, preliminary evidence of clinical activity, and recommended Phase 2 dose (RP2D) of INCMGA00012 in combination with other agents that may improve the therapeutic efficacy of anti-PD-1 monotherapy.

cancer
solid tumors
University of Chicago Medical Center
 (8.8 away) Contact site
  • 25 views
  • 14 Dec, 2020
  • +8 other locations
featured
A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma

The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with metastatic merkel cell carcinoma (MCC).  

merkel cell carcinoma
metastatic cancer
carcinoma
metastatic merkel cell carcinoma
cancer
RUSH UNIVERSITY
 (7.5 away) Contact site
  • 101 views
  • 14 Dec, 2020
  • +6 other locations
featured
GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

graft-versus-host disease
University of Chicago
 (8.8 away) Contact site
  • 1462 views
  • 08 Dec, 2020
  • +10 other locations
featured
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma (516-003)

This is a study involving an investigational (experimental) drug called sitravatinib, given in combination with the immunotherapy nivolumab (also known as OPDIVO®).  Sitravatinib is designed to block specific proteins that are thought to cause tumors to grow and to prevent growth of new blood vessels that help cancer tumors to …

advanced urothelial carcinoma
metastatic urothelial carcinoma
nivolumab
carcinoma
urothelial carcinoma
The University of Chicago
 (8.8 away) Contact site
  • 80 views
  • 02 Jun, 2021
  • +35 other locations
featured
VIVID-1, a clinical research study for adults 18–80 with moderately to severely active Crohn’s disease.

A phase 3 research study of an injectable investigational medicine for adults ages 18 to 80 with moderate to severe Crohn’s disease. Note that study participants may receive the investigational medication, a currently approved Crohn’s medication, or placebo. The study comprises four periods: screening, treatment period 1, treatment period 2, …

gastrointestinal diseases
crohn's disease
gastrointestinal disorder
inflammatory bowel disease
VIVID-1 Study Center
 (7.2 away) Contact site
  • 66 views
  • 20 Jul, 2021
  • +73 other locations